Middle East & Africa Oncology Based Molecular Diagnostics Market Size & Outlook
Middle East & Africa oncology based molecular diagnostics market, 2018-2030 (US$M)
Related Markets
MEA oncology based molecular diagnostics market highlights
- The MEA oncology based molecular diagnostics market generated a revenue of USD 131.8 million in 2024.
- The market is expected to grow at a CAGR of 5.8% from 2025 to 2030.
- In terms of segment, breast cancer was the largest revenue generating type in 2024.
- Breast Cancer is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, UAE is expected to register the highest CAGR from 2025 to 2030.
MEA data book summary
| Market revenue in 2024 | USD 131.8 million |
| Market revenue in 2030 | USD 188.2 million |
| Growth rate | 5.8% (CAGR from 2025 to 2030) |
| Largest segment | Breast cancer |
| Fastest growing segment | Breast Cancer |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer, Blood Cancer, Kidney Cancer |
| Key market players worldwide | Abbott Laboratories, Bayer AG, Agilent Technologies Inc, Danaher Corp, Hologic Inc, Qiagen NV, Siemens AG, Sysmex Corp, Becton Dickinson & Co, Roche Holding AG ADR |
Other key industry trends
- In terms of revenue, MEA region accounted for 3.3% of the global oncology based molecular diagnostics market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,322.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Oncology based Molecular Diagnostics Market Scope
Oncology based Molecular Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Middle East & Africa oncology based molecular diagnostics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to oncology based molecular diagnostics market will help companies and investors design strategic landscapes.
Breast cancer was the largest segment with a revenue share of 20.79% in 2024. Horizon Databook has segmented the Middle East & Africa oncology based molecular diagnostics market based on breast cancer, prostate cancer, colorectal cancer, cervical cancer, liver cancer, lung cancer, blood cancer, kidney cancer covering the revenue growth of each sub-segment from 2018 to 2030.
MEA includes South Africa and Saudi Arabia. Economic development and presence of high unmet healthcare needs witnessed in the emerging markets such as in South Africa are primary growth drivers of this market.
Reasons to subscribe to Middle East & Africa oncology based molecular diagnostics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa oncology based molecular diagnostics market databook
-
Our clientele includes a mix of oncology based molecular diagnostics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa oncology based molecular diagnostics market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa oncology based molecular diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
MEA oncology based molecular diagnostics market size, by country, 2018-2030 (US$M)
Middle East & Africa Oncology based Molecular Diagnostics Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
